High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
Abstract Isavuconazole exposure–response relationships have been studied with a focus on total rather than unbound exposure, assuming a constant unbound fraction of 1%. We observed a median (range) unbound fraction of 1.59% (0.42–5.30%) in patients. This highly variable protein binding asks for re-evaluation of current pharmacokinetic and pharmacodynamic targets for isavuconazole..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Clinical pharmacokinetics - 62(2023), 12 vom: 11. Okt., Seite 1695-1699 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jansen, Anouk M. E. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s40262-023-01311-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05389989X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05389989X | ||
| 003 | DE-627 | ||
| 005 | 20240405064724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231129s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40262-023-01311-w |2 doi | |
| 035 | |a (DE-627)SPR05389989X | ||
| 035 | |a (SPR)s40262-023-01311-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a 44.00 |2 bkl | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Jansen, Anouk M. E. |e verfasserin |0 (orcid)0000-0002-4736-6515 |4 aut | |
| 245 | 1 | 0 | |a High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Abstract Isavuconazole exposure–response relationships have been studied with a focus on total rather than unbound exposure, assuming a constant unbound fraction of 1%. We observed a median (range) unbound fraction of 1.59% (0.42–5.30%) in patients. This highly variable protein binding asks for re-evaluation of current pharmacokinetic and pharmacodynamic targets for isavuconazole. | ||
| 700 | 1 | |a ter Heine, Rob |e verfasserin |4 aut | |
| 700 | 1 | |a Verweij, Paul E. |e verfasserin |4 aut | |
| 700 | 1 | |a Brüggemann, Roger J. M. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacokinetics |d Springer International Publishing, 1976 |g 62(2023), 12 vom: 11. Okt., Seite 1695-1699 |w (DE-627)SPR033030669 |w (DE-600)2043781-X |x 1179-1926 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:12 |g day:11 |g month:10 |g pages:1695-1699 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40262-023-01311-w |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.00 |q VZ |
| 936 | b | k | |a 44.40 |q VZ |
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 12 |b 11 |c 10 |h 1695-1699 | ||